Search clinical trials for: BIBW 2948 BS

Total 349 results

Huiqiang Huang

Unknown

Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation

Lymphoma, Extranodal NK-T-Cell | EBV
Boehringer Ingelheim

Completed

Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

Healthy
National University Hospital, Singapore

Completed

Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)

Non Alcoholic Steatohepatitis

Singapore
Boehringer Ingelheim

Completed

A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer

Prostatic Neoplasms
ETOP IBCSG Partners Foundation

Completed

Afatinib in NSCLC With HER2 Mutation (NICHE)

NSCLC

Switzerland, Germany, Spain, Netherlands
Universitätsklinikum Hamburg-Eppendorf
Boehringer Ingelheim

Terminated

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Refractory Cancer

Germany
Gesynta Pharma AB
CTC Clinical Trial Consultants AB

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248

Healthy

Sweden
University College, London
Boehringer Ingelheim

Completed

Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients (TIMELY)

Carcinoma, Non-Small-Cell Lung

United Kingdom
Boehringer Ingelheim

Completed

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Canada, China, France, Germany, Hong Kong, Italy, Korea, Republic of, Netherlands, Singapore, Spain, Taiwan, Thailand, United Kingdom
Boehringer Ingelheim

Completed

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Boehringer Ingelheim

Terminated

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Neoplasms

United States, Taiwan
Instituto Nacional de Cancerologia de Mexico

Completed

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | EGFR | HER-2

Mexico
University of Reading

Completed

An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men

Vasodilation

United Kingdom
Boehringer Ingelheim

Completed

Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Centre Hospitalier St Anne
Roche Pharma AG

Not yet recruiting

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease (GliSyn)

Alzheimer Disease

France
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIRT 1696 BS in Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers

Healthy
Boehringer Ingelheim

Completed

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

Neoplasms

Belgium
University of Reading

Unknown

The Vascular and Cognitive Effects of Chronic High-flavanol Intake in Healthy Males

Healthy
Kyowa Kirin Korea Co., Ltd.

Terminated

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma | Phase 2 Portion : Small Cell Lung Cancer(SCLC)

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

Healthy
Haukeland University Hospital

Completed

Hypertonic Saline-hetastarch in Cardiac Surgery (HH)

Postoperative Cardiorespiratory Failure

Norway
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis

Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan and more
Washington University School of Medicine
Roche Pharma AG

Recruiting

R21 Roche: 3-Way Tau Tracers in AD

Alzheimer Disease

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

Head and Neck Squamous Cell Carcinoma

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Carcinoid Tumor | Neuroendocrine Neoplasm | Metastatic Carcinoid Tumor

United States
University College, London
Boehringer Ingelheim

Completed

Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer (METRO-BIBF)

Ovarian Cancer | Fallopian Tube Cancer

United Kingdom
Boehringer Ingelheim

Completed

Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers

Healthy
Shandong University

Completed

Detection of Early Gastric Cancers Using Confocal Laser Endomicroscopy (CLE)

Stomach Neoplasms | Precancerous Conditions

China
Boehringer Ingelheim

Completed

BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male Volunteers

Healthy
Aga Khan University Hospital, Pakistan
Harvard Medical School (HMS and HSDM); University of Oxford; International Vaccine... and other collaborators

Not yet recruiting

Combination Assessment Trial of COVID-19 Vaccines (COMBAT-COVID) (COMBAT-COVID)

COVID 19 Vaccine

Pakistan
Johns Hopkins University
National Institute on Aging (NIA)

Withdrawn

Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients

Healthy | Alzheimer Disease

United States
Boehringer Ingelheim

Completed

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Austria, Germany, Spain, China, Taiwan, Argentina, Australia, Belgium, Brazil, Finland, France, Hungary, India, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Russian Federation, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) in Head & Neck Cancer

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States, Belgium, France, Spain
Boehringer Ingelheim

Completed

Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects

Healthy
Northwestern University
National Cancer Institute (NCI); Boehringer Ingelheim; Robert H. Lurie Cancer...

Active, not recruiting

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Fibroblast Growth Factor Basic Form Measurement | FLT3 Internal Tandem Duplication

United States
Boehringer Ingelheim

Completed

Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects

Healthy
National Taiwan University Hospital

Recruiting

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

NSCLC Stage IV

Taiwan
Boehringer Ingelheim

Completed

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Netherlands
Boehringer Ingelheim

Completed

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Neoplasms
Boehringer Ingelheim

Completed

Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers

Healthy
Lee's Pharmaceutical Limited

Unknown

Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients

High-grade Gliomas

China
Apollo Endosurgery, Inc.

Completed

A Study of BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects

Obesity

United States
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Neoplasms

3

Subscribe